Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | FASN | P49327 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8398214 | 1.00 | ALDH1A1 (0.44) | ALDH1A1TSHRCYP1A2HTTSMN1; SMN2 | |
| SCHEMBL10416344 | 1.00 | ALDH1A1 (0.44) | ALDH1A1TSHRCYP1A2HTTSMN1; SMN2 | |
| SCHEMBL8398070 | 0.98 | ALDH1A1 (0.42) | ALDH1A1TSHRCYP1A2HTTSMN1; SMN2 | |
| SCHEMBL8394016 | 0.93 | ALDH1A1 (0.40) | ALDH1A1TSHRCYP1A2HTTSMN1; SMN2 | |
| SCHEMBL8398149 | 0.85 | ALDH1A1 (0.35) | ALDH1A1TSHRCYP1A2 | |
| SCHEMBL11046181 | 0.82 | ALDH1A1 (0.62) | ALDH1A1TSHRCYP1A2HTTSMN1; SMN2 | |
| SCHEMBL8529727 | 0.82 | ALDH1A1 (0.62) | ALDH1A1TSHRCYP1A2HTTSMN1; SMN2 | |
| SCHEMBL351953 | 0.82 | ALDH1A1 (0.62) | ALDH1A1TSHRCYP1A2HTTSMN1; SMN2 | |
| SCHEMBL21722512 | 0.82 | ALDH1A1 (0.62) | ALDH1A1TSHRCYP1A2HTTSMN1; SMN2 | |
| SCHEMBL21722823 | 0.82 | ALDH1A1 (0.62) | ALDH1A1TSHRCYP1A2HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579375-B2 | Branched carboxylic acid compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-08-25 | — | — | US | disclosed |
| US-20070167522-A1 | Branched carboxylic acid compound and use thereof | ONO PHARMACEUTICAL CO LTD | 2007-07-19 | — | — | US | disclosed |
| EP-1650182-A1 | BRANCHED CARBOXYLIC ACID COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167522-A1 | Branched carboxylic acid compound and use thereof | BDNF, CA1, BACE1 | ALDH1A1 23/4885TSHR 4354/4885CYP1A2 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.